Genmab Updates FY24 Revenue Guidance From DKK 18.7B – 20.5B To DKK 20.5B – 21.7B, Reflecting Continued Strong Growth Of DARZALEX And Kesimpta Net Sales
Portfolio Pulse from Benzinga Newsdesk
Genmab A/S (NASDAQ:GMAB) has updated its 2024 financial guidance, increasing its revenue forecast from DKK 18.7-20.5 billion to DKK 20.5-21.7 billion. This revision is driven by higher royalties, reimbursement revenue, and strong sales of DARZALEX and Kesimpta. The update follows Genmab's acquisition of ProfoundBio, Inc., and includes incremental R&D investments and acquisition-related charges.
August 08, 2024 | 3:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Genmab A/S has increased its 2024 revenue guidance to DKK 20.5-21.7 billion, driven by higher royalties, reimbursement revenue, and strong sales of DARZALEX and Kesimpta. The update follows the acquisition of ProfoundBio, Inc., and includes incremental R&D investments and acquisition-related charges.
The increase in revenue guidance is a positive indicator for Genmab's financial health and growth prospects. The strong sales of key products and higher royalties suggest robust performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100